Strategic partnership to expand OOC solutions distribution in Japan

CN Bio, a leading provider of Organ-on-a-Chip (OOC) systems designed to enhance drug discovery and development workflows, has announced a strategic partnership with Primetech Corporation, a Japanese distributor of life sciences research equipment. This agreement establishes a direct distribution channel for CN Bio’s OOC solutions in Japan, providing customers with localised support and technical expertise.

Driven by shifting global regulations and an increasing push for new approach methodologies (NAMs), the demand for OOC solutions in Japan is accelerating. The country’s OOC market is forecast to reach $28.2 million by 2030, growing at a compound annual growth rate (CAGR) of 30.7%. Pharmaceutical and biotech companies are increasingly adopting OOC technologies to improve preclinical drug development, which reduces failure rates and accelerates the discovery of new therapeutics. The partnership with Primetech will allow CN Bio to meet the growing market demand by expanding its reach within the Asia-Pacific region.

CN Bio’s PhysioMimix® OOC systems accurately replicate human physiology in the lab, providing more reliable predictions of drug responses. These advanced in vitro models help reduce reliance on animal testing while offering critical insights into drug bioavailability, toxicology, and disease modelling. With these systems, researchers can better assess the efficacy and safety of drug candidates early in the development process, minimising costly late-stage failures.

Ryosuke Ogihara, CEO of Primetech Corporation, commented: “We are excited to begin our partnership with CN Bio to offer their innovative microphysiological systems and reagents. These cutting-edge solutions have the potential to significantly accelerate the drug discovery process, and we are confident they will drive research efficiency and success for our customers.”

Dr Paul Brooks, CEO of CN Bio, added: “Partnering with Primetech is a key step in our global growth strategy. It allows us to expand our distribution network in Japan, providing direct support and addressing the increasing demand for our OOC solutions. This agreement underscores our commitment to delivering world-class OOC technologies and transforming drug discovery globally.”

More information online